Investigational VEGF antagonists for psoriasis (Q37956733)

25 August 2017

Investigational VEGF antagonists for psoriasis (English)

1 reference

25 August 2017

A A Crawshaw

1

1 reference

25 August 2017

C E M Griffiths

series ordinal

2

1 reference

25 August 2017

H S Young

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

16 November 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

21

1 reference

25 August 2017

1

1 reference

25 August 2017

33-43

1 reference

Pathogenesis and clinical features of psoriasis

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

VEGF/VEGFR signalling as a target for inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Targeting angiogenesis in cancer: clinical development of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Preferred therapies for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Improvement of psoriasis during sunitinib therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

21 January 2018

Psoriasis: epidemiology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Selective down-regulation of IP(3)receptor subtypes by caspases and calpain during TNF alpha -induced apoptosis of human T-lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Therapeutic anti-VEGF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Current and future management of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Complete remission of psoriasis following bevacizumab therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.636351

10.1517/13543784.2012.636351

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference